title: Extremely low levels of epidermal skin-derived antileucoproteinase/elafin in a patient with impetigo herpetiformis.
abstract: Impetigo herpetiformis (IH) is a rare pustular dermatosis with unknown aetiology, typically occurring during pregnancy. Based upon a similar clinical and histological presentation, i.e. spongiform accumulation of polymorphonuclear leucocytes in the stratum corneum, several authors consider IH as a variant of generalized pustular psoriasis (GPP), while others state that IH is a separate entity. Skin-derived antileucoproteinase (SKALP) is a strong and specific inhibitor of human leucocyte elastase (HLE) and proteinase 3, two neutral proteinases that have been implicated in leucocyte migration and tissue destruction. Previously, we reported decreased SKALP activity in pustular forms of psoriasis compared with plaque psoriasis. In this study we present a case study of a patient with IH, where SKALP activity was measured using biochemical and immunochemical techniques. Epidermal scales and sera were collected during the course of the disease. Comparison was made with three patients with GPP and six patients with plaque psoriasis. Initially, anti-HLE activity in epidermal scales of the patient with IH was comparable with values in patients with GPP, i.e. decreased compared with plaque psoriasis. During the course of the disease, anti-elastase activity dropped to undetectable levels, concomitant with the appearance of free elastase activity. This finding suggests a total saturation of epidermal anti-HLE activity. Low levels of SKALP, presumably complexed with HLE, could be measured immunochemically in scale extracts. Serum levels of total SKALP correlated with the disease activity. We suggest that a reduced amount of epidermal SKALP contributes to an imbalance between elastase and its inhibitor, resulting in the formation of epidermal pustules. This mechanism of pustule formation could apply both to GPP and IH, suggesting a final common pathway in the pathogenic mechanisms of IH and GPP.
authors.affiliation: Department of Dermatology, University Hospital Nijmegen, The Netherlands.
authors.forename: A L
authors.initials: AL
authors.lastname: Kuijpers
authors.forename: J
authors.initials: J
authors.lastname: Schalkwijk
authors.forename: H F
authors.initials: HF
authors.lastname: Rulo
authors.forename: J J
authors.initials: JJ
authors.lastname: Peperkamp
authors.forename: P C
authors.initials: PC
authors.lastname: van de Kerkhof
authors.forename: E M
authors.initials: EM
authors.lastname: de Jong
mesh_terms: D000328:Adult; D004797:Enzyme-Linked Immunosorbent Assay; D004817:Epidermis / Q000201:enzymology*; D005260:Female; D006801:Humans; D007169:Impetigo / Q000097:blood / Q000188:drug therapy / Q000201:enzymology*; D015474:Isotretinoin / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000188:drug therapy / Q000201:enzymology*; D011263:Pregnancy Trimester, Third; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins / Q000032:analysis*; D011565:Psoriasis / Q000201:enzymology; D015842:Serine Proteinase Inhibitors / Q000032:analysis* / Q000097:blood
chemical_list: D007641:Keratolytic Agents; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins; D015842:Serine Proteinase Inhibitors; D015474:Isotretinoin